Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes

Insights from the SUSTAIN 1–7 trials

V. R. Aroda, Andrew Ahmann, B. Cariou, F. Chow, M. J. Davies, E. Jódar, R. Mehta, V. Woo, I. Lingvay

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications. Guidelines recommend treatment goals targeting HbA 1c , body weight, blood pressure, and low-density lipoprotein cholesterol. Development of new treatments for type 2 diabetes requires an understanding of their mechanism and efficacy, as well as their relative effects compared to other treatment choices, plus demonstration of cardiovascular safety. Subcutaneous semaglutide is a glucagon-like peptide-1 receptor agonist currently approved in several countries for once-weekly treatment of type 2 diabetes. Semaglutide works via the incretin pathway, stimulating insulin and inhibiting glucagon secretion from the pancreatic islets, leading to lower blood glucose levels. Semaglutide also decreases energy intake by reducing appetite and food cravings, and lowering relative preference for fatty, energy-dense foods. Semaglutide was evaluated in the SUSTAIN clinical trial programme in over 8000 patients across the spectrum of type 2 diabetes. This review details the efficacy and safety profile of semaglutide in the SUSTAIN 1–5 and 7 trials, and its cardiovascular safety profile in the SUSTAIN 6 trial. Semaglutide consistently demonstrated superior and sustained glycemic control and weight loss vs. all comparators evaluated. In SUSTAIN 6, involving patients at high risk of cardiovascular disease, semaglutide significantly decreased the occurrence of cardiovascular events compared with placebo/standard of care (hazard ratio 0.74, P < 0.001 for non-inferiority). Through a comprehensive phase 3 clinical trial program, we have a detailed understanding of semaglutide's efficacy, safety, cardiovascular effects and comparative role in the treatment of type 2 diabetes.

Original languageEnglish (US)
JournalDiabetes and Metabolism
DOIs
StatePublished - Jan 1 2019

Fingerprint

Type 2 Diabetes Mellitus
Safety
Therapeutics
Incretins
Food
Phase III Clinical Trials
semaglutide
Risk Management
Appetite
Diabetes Complications
Standard of Care
Energy Intake
Glucagon
Islets of Langerhans
LDL Cholesterol
Blood Glucose
Weight Loss
Cardiovascular Diseases
Placebos
Body Weight

Keywords

  • Cardiovascular
  • Efficacy
  • Glucagon-like peptide-1 receptor agonist
  • Semaglutide, SUSTAIN
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes : Insights from the SUSTAIN 1–7 trials. / Aroda, V. R.; Ahmann, Andrew; Cariou, B.; Chow, F.; Davies, M. J.; Jódar, E.; Mehta, R.; Woo, V.; Lingvay, I.

In: Diabetes and Metabolism, 01.01.2019.

Research output: Contribution to journalReview article

Aroda, V. R. ; Ahmann, Andrew ; Cariou, B. ; Chow, F. ; Davies, M. J. ; Jódar, E. ; Mehta, R. ; Woo, V. ; Lingvay, I. / Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes : Insights from the SUSTAIN 1–7 trials. In: Diabetes and Metabolism. 2019.
@article{25b20458ee774e98a287467e75af7741,
title = "Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials",
abstract = "In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications. Guidelines recommend treatment goals targeting HbA 1c , body weight, blood pressure, and low-density lipoprotein cholesterol. Development of new treatments for type 2 diabetes requires an understanding of their mechanism and efficacy, as well as their relative effects compared to other treatment choices, plus demonstration of cardiovascular safety. Subcutaneous semaglutide is a glucagon-like peptide-1 receptor agonist currently approved in several countries for once-weekly treatment of type 2 diabetes. Semaglutide works via the incretin pathway, stimulating insulin and inhibiting glucagon secretion from the pancreatic islets, leading to lower blood glucose levels. Semaglutide also decreases energy intake by reducing appetite and food cravings, and lowering relative preference for fatty, energy-dense foods. Semaglutide was evaluated in the SUSTAIN clinical trial programme in over 8000 patients across the spectrum of type 2 diabetes. This review details the efficacy and safety profile of semaglutide in the SUSTAIN 1–5 and 7 trials, and its cardiovascular safety profile in the SUSTAIN 6 trial. Semaglutide consistently demonstrated superior and sustained glycemic control and weight loss vs. all comparators evaluated. In SUSTAIN 6, involving patients at high risk of cardiovascular disease, semaglutide significantly decreased the occurrence of cardiovascular events compared with placebo/standard of care (hazard ratio 0.74, P < 0.001 for non-inferiority). Through a comprehensive phase 3 clinical trial program, we have a detailed understanding of semaglutide's efficacy, safety, cardiovascular effects and comparative role in the treatment of type 2 diabetes.",
keywords = "Cardiovascular, Efficacy, Glucagon-like peptide-1 receptor agonist, Semaglutide, SUSTAIN, Type 2 diabetes",
author = "Aroda, {V. R.} and Andrew Ahmann and B. Cariou and F. Chow and Davies, {M. J.} and E. J{\'o}dar and R. Mehta and V. Woo and I. Lingvay",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.diabet.2018.12.001",
language = "English (US)",
journal = "Diabete et Metabolisme",
issn = "0338-1684",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes

T2 - Insights from the SUSTAIN 1–7 trials

AU - Aroda, V. R.

AU - Ahmann, Andrew

AU - Cariou, B.

AU - Chow, F.

AU - Davies, M. J.

AU - Jódar, E.

AU - Mehta, R.

AU - Woo, V.

AU - Lingvay, I.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications. Guidelines recommend treatment goals targeting HbA 1c , body weight, blood pressure, and low-density lipoprotein cholesterol. Development of new treatments for type 2 diabetes requires an understanding of their mechanism and efficacy, as well as their relative effects compared to other treatment choices, plus demonstration of cardiovascular safety. Subcutaneous semaglutide is a glucagon-like peptide-1 receptor agonist currently approved in several countries for once-weekly treatment of type 2 diabetes. Semaglutide works via the incretin pathway, stimulating insulin and inhibiting glucagon secretion from the pancreatic islets, leading to lower blood glucose levels. Semaglutide also decreases energy intake by reducing appetite and food cravings, and lowering relative preference for fatty, energy-dense foods. Semaglutide was evaluated in the SUSTAIN clinical trial programme in over 8000 patients across the spectrum of type 2 diabetes. This review details the efficacy and safety profile of semaglutide in the SUSTAIN 1–5 and 7 trials, and its cardiovascular safety profile in the SUSTAIN 6 trial. Semaglutide consistently demonstrated superior and sustained glycemic control and weight loss vs. all comparators evaluated. In SUSTAIN 6, involving patients at high risk of cardiovascular disease, semaglutide significantly decreased the occurrence of cardiovascular events compared with placebo/standard of care (hazard ratio 0.74, P < 0.001 for non-inferiority). Through a comprehensive phase 3 clinical trial program, we have a detailed understanding of semaglutide's efficacy, safety, cardiovascular effects and comparative role in the treatment of type 2 diabetes.

AB - In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications. Guidelines recommend treatment goals targeting HbA 1c , body weight, blood pressure, and low-density lipoprotein cholesterol. Development of new treatments for type 2 diabetes requires an understanding of their mechanism and efficacy, as well as their relative effects compared to other treatment choices, plus demonstration of cardiovascular safety. Subcutaneous semaglutide is a glucagon-like peptide-1 receptor agonist currently approved in several countries for once-weekly treatment of type 2 diabetes. Semaglutide works via the incretin pathway, stimulating insulin and inhibiting glucagon secretion from the pancreatic islets, leading to lower blood glucose levels. Semaglutide also decreases energy intake by reducing appetite and food cravings, and lowering relative preference for fatty, energy-dense foods. Semaglutide was evaluated in the SUSTAIN clinical trial programme in over 8000 patients across the spectrum of type 2 diabetes. This review details the efficacy and safety profile of semaglutide in the SUSTAIN 1–5 and 7 trials, and its cardiovascular safety profile in the SUSTAIN 6 trial. Semaglutide consistently demonstrated superior and sustained glycemic control and weight loss vs. all comparators evaluated. In SUSTAIN 6, involving patients at high risk of cardiovascular disease, semaglutide significantly decreased the occurrence of cardiovascular events compared with placebo/standard of care (hazard ratio 0.74, P < 0.001 for non-inferiority). Through a comprehensive phase 3 clinical trial program, we have a detailed understanding of semaglutide's efficacy, safety, cardiovascular effects and comparative role in the treatment of type 2 diabetes.

KW - Cardiovascular

KW - Efficacy

KW - Glucagon-like peptide-1 receptor agonist

KW - Semaglutide, SUSTAIN

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85065773014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065773014&partnerID=8YFLogxK

U2 - 10.1016/j.diabet.2018.12.001

DO - 10.1016/j.diabet.2018.12.001

M3 - Review article

JO - Diabete et Metabolisme

JF - Diabete et Metabolisme

SN - 0338-1684

ER -